A phase II study of carboplatin plus gemcitabine in advanced non-small-cell lung cancer (NSCLC) - A hoosier oncology group study

被引:27
|
作者
Ng, EW
Sandler, AB
Robinson, L
Einhorn, LH
机构
[1] Indiana Univ, Dept Med, Hematol Oncol Sect, Indianapolis, IN USA
[2] Ft Wayne Med Oncol & Hematol, Ft Wayne, IN USA
关键词
carboplatin; gemcitabine; non-small-cell lung cancer;
D O I
10.1097/00000421-199912000-00003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The purpose of this study was to evaluate the toxicity and determine the response rate, duration of remission, and survival using gemcitabine plus carboplatin in non-small cell lung cancer (NSCLC). This was a phase ii study of gemcitabine and carboplatin in chemotherapy-naive patients with advanced NSCLC and Karnofsky Performance Status of at least 80. Gemcitabine was administered intravenously at 1,000 mg/m(2) weekly for 3 weeks followed by 1 week rest. Carboplatin was administered immediately after gemcitabine at an area under the curve (AUC) of 5 given intravenously on day 1 of an every-4-week cycle. Seven patients were entered in the study and five were evaluable For toxicity. The median age of patients was 68 years (range, 52-72). The protocol was prematurely terminated because of severe and unexpected hematologic toxicity. Grade 3-4 thrombocytopenia was observed in four of the first five patients. These toxicities were all observed with the first course of chemotherapy. There were no objective responses seen. Median survival time was 130 days. Carboplatin plus gemcitabine was a logical combination. However, because of the severe thrombocytopenia associated with this regimen, we do not recommend this two-drug combination in the dose and schedule used in this study.
引用
收藏
页码:550 / 553
页数:4
相关论文
共 50 条
  • [2] Phase II study of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer
    Wang, Lin Run
    Huang, Ming Zhu
    Zhang, Guo Bing
    Xu, Nong
    Wu, Xiu Hua
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 60 (04) : 601 - 607
  • [3] Phase II study of gemcitabine and carboplatin in patients with advanced non-small-cell lung cancer
    Lin Run Wang
    Ming Zhu Huang
    Guo Bing Zhang
    Nong Xu
    Xiu Hua Wu
    [J]. Cancer Chemotherapy and Pharmacology, 2007, 60 : 601 - 607
  • [4] Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: A Hoosier Oncology Group study
    Schneider, BP
    Ganjoo, KN
    Seitz, DE
    Picus, J
    Fata, F
    Stoner, C
    Calley, C
    Loehrer, PJ
    [J]. ONCOLOGY, 2003, 65 (03) : 218 - 223
  • [5] Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study
    D. R. Gandara
    Martin J. Edelman
    John J. Crowley
    Derick H. M. Lau
    Robert B. Livingston
    [J]. Cancer Chemotherapy and Pharmacology, 1997, 41 : 75 - 78
  • [6] Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study
    Gandara, DR
    Edelman, MJ
    Crowley, JJ
    Lau, DHM
    Livingston, RB
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1997, 41 (01) : 75 - 78
  • [7] Combination chemotherapy with carboplatin, docetaxel, and gemcitabine in advanced non-small-cell lung cancer: A phase II study
    Pectasides, D
    Aspropotamitis, A
    Halikia, A
    Visvikis, A
    Antoniou, F
    Kalantaridou, A
    Karvounis, N
    Batzios, S
    Athanassiou, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (12) : 3816 - 3821
  • [8] Gemcitabine plus cisplatin in advanced non-small cell lung cancer (NSCLC): A phase II study
    Orlandi-Jorquera, L
    Orlandi, F
    Galaz, P
    Gamargo, C
    Salman, P
    Yanez, M
    [J]. ANNALS OF ONCOLOGY, 1998, 9 : 101 - 101
  • [9] Phase III Study by the Norwegian Lung Cancer Study Group: Pemetrexed Plus Carboplatin Compared With Gemcitabine Plus Carboplatin As First-Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer
    Gronberg, Bjorn H.
    Bremnes, Roy M.
    Flotten, Oystein
    Amundsen, Tore
    Brunsvig, Paal Fr.
    Hjelde, Harald H.
    Kaasa, Stein
    von Plessen, Christian
    Stornes, Froydis
    Tollali, Terje
    Wammer, Finn
    Aasebo, Ulf
    Sundstrom, Stein
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) : 3217 - 3224
  • [10] Carboplatin plus gemcitabine followed by weekly paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC): A phase II study
    Tjan-Heijnen, V
    Timmer-Bonte, J
    van der Drift, M
    van Leeuwen, F
    de Boo, T
    Wagenaar, M
    van Die, L
    Bussink, J
    [J]. LUNG CANCER, 2005, 49 : S272 - S272